scholarly journals Rapid generation of OPC-like cells from human pluripotent stem cells for treating spinal cord injury

2017 ◽  
Vol 49 (7) ◽  
pp. e361-e361 ◽  
Author(s):  
Dae-Sung Kim ◽  
Se Jung Jung ◽  
Jae Souk Lee ◽  
Bo Young Lim ◽  
Hyun Ah Kim ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Spinal Cord Injury ◽  
Pluripotent Stem Cells ◽  
Human Pluripotent Stem Cells ◽  
Cord Injury ◽  
Rapid Generation

scholarly journals Concise Review: Human Pluripotent Stem Cells in the Treatment of Spinal Cord Injury

Stem Cells ◽  
2012 ◽  
Vol 30 (9) ◽  
pp. 1787-1792 ◽  
Author(s):  
Dunja Lukovic ◽  
Victoria Moreno Manzano ◽  
Miodrag Stojkovic ◽  
Shom Shanker Bhattacharya ◽  
Slaven Erceg
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Spinal Cord Injury ◽  
Pluripotent Stem Cells ◽  
Human Pluripotent Stem Cells ◽  
Concise Review ◽  
Cord Injury

Human Pluripotent Stem Cells for Spinal Cord Injury

2020 ◽  
Vol 15 (2) ◽  
pp. 135-143 ◽  
Author(s):  
Maryam Farzaneh ◽  
Amir Anbiyaiee ◽  
Seyed Esmaeil Khoshnam
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Spinal Cord Injury ◽  
Pluripotent Stem Cells ◽  
Embryonic Stem ◽  
Human Pluripotent Stem Cells ◽  
Patient Specific ◽  
Public Health Issue ◽  
In Vivo Models ◽  
Cord Injury

Spinal cord injury (SCI) as a serious public health issue and neurological insult is one of the most severe cause of long-term disability. To date, a variety of techniques have been widely developed to treat central nervous system injury. Currently, clinical treatments are limited to surgical decompression and pharmacotherapy. Because of their negative effects and inefficiency, novel therapeutic approaches are required in the management of SCI. Improvement and innovation of stem cell-based therapies have a huge potential for biological and future clinical applications. Human pluripotent stem cells (hPSCs) including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are defined by their abilities to divide asymmetrically, self-renew and ultimately differentiate into various cell lineages. There are considerable research efforts to use various types of stem cells, such as ESCs, neural stem cells (NSCs), and mesenchymal stem cells (MSCs) in the treatment of patients with SCI. Moreover, the use of patient-specific iPSCs holds great potential as an unlimited cell source for generating in vivo models of SCI. In this review, we focused on the potential of hPSCs in treating SCI.

scholarly journals Long-Distance Axonal Growth from Human Induced Pluripotent Stem Cells after Spinal Cord Injury

Neuron ◽  
2014 ◽  
Vol 83 (4) ◽  
pp. 789-796 ◽  
Author(s):  
Paul Lu ◽  
Grace Woodruff ◽  
Yaozhi Wang ◽  
Lori Graham ◽  
Matt Hunt ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Spinal Cord Injury ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Axonal Growth ◽  
Long Distance ◽  
Cord Injury ◽  
Induced Pluripotent

scholarly journals Stem Cell Secretome for Spinal Cord Repair: Is It More than Just a Random Baseline Set of Factors?

Cells ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 3214
Author(s):  
Krisztián Pajer ◽  
Tamás Bellák ◽  
Antal Nógrádi
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Spinal Cord Injury ◽  
Pluripotent Stem Cells ◽  
Spinal Cord Injuries ◽  
New Era ◽  
Experimental Application ◽  
Cord Injury ◽  
Induced Pluripotent ◽  
Spinal Cord Repair

Hundreds of thousands of people suffer spinal cord injuries each year. The experimental application of stem cells following spinal cord injury has opened a new era to promote neuroprotection and neuroregeneration of damaged tissue. Currently, there is great interest in the intravenous administration of the secretome produced by mesenchymal stem cells in acute or subacute spinal cord injuries. However, it is important to highlight that undifferentiated neural stem cells and induced pluripotent stem cells are able to adapt to the damaged environment and produce the so-called lesion-induced secretome. This review article focuses on current research related to the secretome and the lesion-induced secretome and their roles in modulating spinal cord injury symptoms and functional recovery, emphasizing different compositions of the lesion-induced secretome in various models of spinal cord injury.

scholarly journals Early Intervention for Spinal Cord Injury with Human Induced Pluripotent Stem Cells Oligodendrocyte Progenitors

PLoS ONE ◽  
2015 ◽  
Vol 10 (1) ◽  
pp. e0116933 ◽  
Author(s):  
Angelo H. All ◽  
Payam Gharibani ◽  
Siddharth Gupta ◽  
Faith A. Bazley ◽  
Nikta Pashai ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Spinal Cord Injury ◽  
Early Intervention ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Oligodendrocyte Progenitors ◽  
Cord Injury ◽  
Induced Pluripotent

scholarly journals Differentiation of V2a interneurons from human pluripotent stem cells

2017 ◽  
Vol 114 (19) ◽  
pp. 4969-4974 ◽  
Author(s):  
Jessica C. Butts ◽  
Dylan A. McCreedy ◽  
Jorge Alexis Martinez-Vargas ◽  
Frederico N. Mendoza-Camacho ◽  
Tracy A. Hookway ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Neural Tube ◽  
Pluripotent Stem Cells ◽  
Central Pattern Generators ◽  
Neuronal Cell ◽  
Nervous System Development ◽  
Human Pluripotent Stem Cells ◽  
Neural Lineage ◽  
Cord Injury

The spinal cord consists of multiple neuronal cell types that are critical to motor control and arise from distinct progenitor domains in the developing neural tube. Excitatory V2a interneurons in particular are an integral component of central pattern generators that control respiration and locomotion; however, the lack of a robust source of human V2a interneurons limits the ability to molecularly profile these cells and examine their therapeutic potential to treat spinal cord injury (SCI). Here, we report the directed differentiation of CHX10+ V2a interneurons from human pluripotent stem cells (hPSCs). Signaling pathways (retinoic acid, sonic hedgehog, and Notch) that pattern the neural tube were sequentially perturbed to identify an optimized combination of small molecules that yielded ∼25% CHX10+ cells in four hPSC lines. Differentiated cultures expressed much higher levels of V2a phenotypic markers (CHX10 and SOX14) than other neural lineage markers. Over time, CHX10+ cells expressed neuronal markers [neurofilament, NeuN, and vesicular glutamate transporter 2 (VGlut2)], and cultures exhibited increased action potential frequency. Single-cell RNAseq analysis confirmed CHX10+ cells within the differentiated population, which consisted primarily of neurons with some glial and neural progenitor cells. At 2 wk after transplantation into the spinal cord of mice, hPSC-derived V2a cultures survived at the site of injection, coexpressed NeuN and VGlut2, extended neurites >5 mm, and formed putative synapses with host neurons. These results provide a description of V2a interneurons differentiated from hPSCs that may be used to model central nervous system development and serve as a potential cell therapy for SCI.

Sign in / Sign up

Export Citation Format

Share Document